Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA)
Détails
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_637F303A3705
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA)
Périodique
Br J Sports Med
Collaborateur⸱rice⸱s
Orcca Investigators
ISSN
1473-0480 (Electronic)
0306-3674 (Print)
0306-3674 (Print)
ISSN-L
0306-3674
Statut éditorial
Publié
Date de publication
08/2022
Volume
56
Numéro
16
Pages
913-918
Langue
anglais
Notes
Petek, Bradley J
Moulson, Nathaniel
Baggish, Aaron L
Kliethermes, Stephanie A
Patel, Manesh R
Churchill, Timothy W
Harmon, Kimberly G
Drezner, Jonathan A
eng
Observational Study
England
Br J Sports Med. 2022 Aug;56(16):913-918. doi: 10.1136/bjsports-2021-104644. Epub 2021 Nov 1.
Moulson, Nathaniel
Baggish, Aaron L
Kliethermes, Stephanie A
Patel, Manesh R
Churchill, Timothy W
Harmon, Kimberly G
Drezner, Jonathan A
eng
Observational Study
England
Br J Sports Med. 2022 Aug;56(16):913-918. doi: 10.1136/bjsports-2021-104644. Epub 2021 Nov 1.
Résumé
OBJECTIVE: To assess the prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms in young competitive athletes following SARS-CoV-2 infection. METHODS: This observational cohort study from the Outcomes Registry for Cardiac Conditions in Athletes included 3597 US collegiate athletes after SARS-CoV-2 infection. Clinical characteristics, advanced diagnostic testing and SARS-CoV-2-associated sequelae were compared between athletes with persistent symptoms >3 weeks, exertional symptoms on return to exercise and those without persistent or exertional symptoms. RESULTS: Among 3597 athletes (mean age 20 years (SD, 1 year), 34% female), data on persistent and exertional symptoms were reported in 3529 and 3393 athletes, respectively. Persistent symptoms >3 weeks were present in 44/3529 (1.2%) athletes with 2/3529 (0.06%) reporting symptoms >12 weeks. Exertional cardiopulmonary symptoms were present in 137/3393 (4.0%) athletes. Clinical evaluation and diagnostic testing led to the diagnosis of SARS-CoV-2-associated sequelae in 12/137 (8.8%) athletes with exertional symptoms (five cardiac involvement, two pneumonia, two inappropriate sinus tachycardia, two postural orthostatic tachycardia syndrome and one pleural effusion). No SARS-CoV-2-associated sequelae were identified in athletes with isolated persistent symptoms. Of athletes with chest pain on return to exercise who underwent cardiac MRI (CMR), 5/24 (20.8%) had probable or definite cardiac involvement. In contrast, no athlete with exertional symptoms without chest pain who underwent CMR (0/20) was diagnosed with probable or definite SARS-CoV-2 cardiac involvement. CONCLUSION: Collegiate athletes with SARS-CoV-2 infection have a low prevalence of persistent or exertional symptoms on return to exercise. Exertional cardiopulmonary symptoms, specifically chest pain, warrant a comprehensive evaluation.
Mots-clé
Adult, Athletes, *COVID-19/diagnosis/epidemiology, Chest Pain, Female, *Heart Diseases/epidemiology, Humans, Male, Prevalence, Registries, SARS-CoV-2, Young Adult, Covid-19, sports, BJSM. ALB has received funding from the National Institute of Health/ National, Heart, Lung, and Blood Institute (NHLBI), the National Football Players, Association, and the American Heart Association and receives compensation for his, role as team cardiologist from the US Olympic Committee / US Olympic Training, Centers, US Soccer, US Rowing, the New England Patriots, the Boston Bruins, the, New England Revolution, and Harvard University. KGH has stock options for, 98point6 for which she is also on the medical advisory board. MRP is on the, Advisory Board for: Amgen, Bayer, Janssen, Heartflow, Medscape, and has research, grant funding from NHLBI, Bayer, Janssen, Heartflow, Idorsia. and the Joel, Cournette Foundation for research on athlete's hearts.
Pubmed
Création de la notice
07/12/2022 12:03
Dernière modification de la notice
25/01/2024 8:37